BCMA-TGFβ CAR-T / Medical College of Wisconsin - LARVOL DELTA

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Trial completion date: May 2028 ➔ May 2029 | Trial primary completion date: May 2027 ➔ May 2028

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • TGFB1

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Trial completion date: Nov 2028 ➔ May 2028 | Initiation date: Mar 2024 ➔ Jun 2024 | Trial primary completion date: Nov 2026 ➔ May 2027

CAR T-Cell Therapy • Trial completion date • Trial initiation date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • TGFB1

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Initiation date: Oct 2023 ➔ Mar 2024

CAR T-Cell Therapy • Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Medical College of Wisconsin

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology